Merck & Co. (MRK) is set to receive expedited FDA review for its oral cholesterol drug enlicitide and cancer therapy sacituzumab tirumotecan (sac-TMT) through the National Priority Voucher program. Enlicitide's application is anticipated in April 2026, while sac-TMT's is expected in late 2026. This program offers a swift one to two-month review. Enlicitide, which achieved its primary and secondary endpoints in a phase 3 trial, differentiates itself from existing injectable PCSK9 therapies. Additionally, Merck secured $700 million in funding from Blackstone Life Sciences to advance sac-TMT.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.